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Diabetic macular edema is a main reason for visual loss in diabetic patients. Until recent years, macular laser photocoagulation
was the only available therapy. The awareness that inﬂammation is an important factor in the pathogenetic process of DME gave
reason for intravitreal treatment with corticosteroids. The introduction of anti-VEGF drugs brought a revolutionary change in the
treatment of DME. This paper will review the important clinical trials with an emphasis on combination therapies.
1.Introduction
Diabetic maculopathy is the main reason for visual loss in
patients with diabetic retinopathy, besides proliferative dia-
betic retinopathy [1–3]. If left untreated, 25–30% of patients
aﬀected by diabetic macular edema (DME) experience a 15-
letter decrease in visual acuity (VA) score within 3 years
[4]. Strict control of glucose levels and blood pressure
signiﬁcantly reduces and delays the onset and severity of
diabetic retinopathy [5, 6].
Available therapies include macular laser photocoagula-
tion, corticosteroids, and anti-VEGF drugs. However, single
treatments are often not eﬀective enough to control DME
during the entire course of the disease which can be very
long. The multifactorial complex pathogenetic mechanisms
require a comprehensive approach.
This paper will review the major trials and recent evi-
dence evaluating both monotherapy and combination treat-
ment for DME.
2. Available Monotherapies
2.1. Macular Laser Photocoagulation. Macular laser photo-
coagulation is a standard of care since shown in 1985 by
the early treatment of diabetic retinopathy study (ETDRS)
to reduce the risk of moderate visual loss in patients with
clinically signiﬁcant macular edema (CSME) by nearly 50%
a t3y e a r s .H o w e v e r ,v i s u a la c u i t y( V A )i m p r o v e m e n ta t3
years, i.e., 15-letter gain, was found in less than 3% of cases
[7]. This apparently slight improvement may be caused by
the fact that 85% of patients had good entry vision (≥20/40).
Still,40%ofthosewithentryVA ≥20/40improved1ormore
lines. Yet, it should be considered that a notable number
of patients stayed unresponsive to photocoagulation. As
explicated below, the DRCR.net found focal/grid laser to be
of greater beneﬁt than monotherapy with triamcinolone [8].
With emergence of anti-VEGF treatment options the role of
macular laser took a back seat in the treatment strategy.
2.2. Intravitreal Corticosteroids. The pathogenesis of DME
is multifactorial. Breakdown of the blood-retina barrier
increases retinal capillary permeability leading to retinal
edema [9–11]. Inﬂammation is an eminent factor in this
process, in particular via leukostasis within retinal capillaries
[12]. The anti-inﬂammatory activity of corticosteroids is
related to several paths of action: corticosteroids interfere
with regulatory components of gene expression and inhibit
the expression of proinﬂammatory genes as TNFα and other
cytokines [13]. At the same time they induce gene function-
ing of anti-inﬂammatory factors, inhibit the phospholipase
A2 pathway, and reduce leucocyte chemotaxis. Vitreous ﬂuid
levels of ICAM-1, IL-6, IL-8, and MCP-1 were found to be
elevated in DME patients [14, 15]. On the other hand VEGF
plays a major role in breakdown of the blood-retina barrier
[16, 17]. Corticosteroids inhibit the expression of VEGF and
VEGF gene [18, 19].2 Journal of Ophthalmology
A multicenter randomized clinical trial by the Dia-
betic Retinopathy Clinical Research Network (DRCR.net)
included 840 eyes and evaluated 1mg and 4mg doses of
preservative-free triamcinolone compared with focal/grid
photocoagulation for DME [20]. At four months, the 4mg
triamcinolone group had better visual acuity but by one year
there were no signiﬁcant diﬀerences. After 16 months and
until the primary outcome visit at 2 years, mean visual acuity
was better in the laser group than in the two triamcinolone
groups. OCT results correlated with visual acuity. Recently,
the DRCR.net published follow-up results of the third year.
Findings were consistent with the 2-year results. More eyes
in all groups improved than worsened. However, patients
in the laser group had a beneﬁt of +5 letters from baseline
compared to the triamcinolone groups which stayed without
change [8].
Expectedly, elevation of intraocular pressure and the
need for cataract surgery were higher in the 4mg triamci-
nolone group. These complications were likewise described
in other studies [21, 22].
2.3. Intravitreal Anti-VEGF Treatment. Am u l t i t u d eo f
proinﬂammatory cytokines are involved in the development
and progression of DME [23]. VEGF has been linked to
leakageofretinalvesselsandhencetotheformationofretinal
edema [24]. This was the rationale for testing anti-VEGF
drugs for the treatment of DME.
2.3.1. Ranibizumab. The Safety and Eﬃcacy of Ranibizumab
in Diabetic Macular Edema (RESOLVE Study)—multicenter,
randomized, and double masked—evaluated the eﬃcacy
and safety of intravitreal ranibizumab (0.3 or 0.5mg)
compared with sham treatment (no ocular injection) in 151
eyes with DME over 12 months [25]. After three monthly
injections treatment could be stopped or reinitiated with an
opportunity for rescue macular laser photocoagulation. The
dosecouldbedoubledafteronemonth.Resultsshowedasig-
niﬁcant and continuous improvement in BCVA and central
retinal thickness for ranibizumab versus sham.
The phase III RIDE and RISE studies evaluated the eﬃ-
cacyandsafetyofranibizumabforDME.RISE(n = 377)and
RIDE (n = 382) are both double-blinded, sham-controlled
randomized studies with a followup of 36 months. Patients
received monthly injections of 0.3mg ranibizumab, 0.5mg
ranibizumab,orsham.PRPwasallowedwhenindicated, and
rescue macular laser was permitted from month 3 onwards.
24-month results were recently presented [26]. In the RISE
study, as twice as many patients in the ranibizumab groups
gained ≥15 letters compared to the sham group (44.8%,
39.2%, and 18.1% in the ranibizumab 0.3mg, 0.5mg,
and sham group, resp.). Results were similar in patients
with better or less controlled glycemia. The RIDE study
showed similar ﬁndings, but there was a clearer beneﬁt for
patients treated with 0.5mg ranibizumab. Moreover, in the
ranibizumab groups there were signiﬁcantly more patients
that achieved VA ≥ 20/40 compared to sham (60% and
63.2% versus 37.8% in RISE and 54.4% and 62.2% versus
34.6% in RIDE). Ranibizumab injections also reduced the
percentage of patients progressing to proliferative diabetic
retinopathy.
2.3.2.Bevacizumab. ThePan-AmericanCollaborativeRetina
Study Group (PACORES) reviewed 139 eyes with DME at
11 centers which received at least one bevacizumab injection
of 1.25 or 2.5mg with a minimum followup of 24 months
[27]. Results showed that at 24 months 44.6% eyes remained
stable, 51.8% improved 2 or more ETDRS lines, and 3.6%
decreased 2 or more lines. Anatomic changes on OCT
paralleled overall functional improvement.
The Bevacizumab or Laser Therapy in the Management
of Diabetic Macular Edema study (BOLT study) is to date the
most meaningful study concerning Bevacizumab for DME
[28]. As a prospective and masked clinical trial with follow-
up of 12 months it randomized 80 patients with CSME and
at least one prior macular laser photocoagulation to Beva-
cizumab injections given every 6 weeks or laser treatment
performed every 4 months. There was a clear beneﬁt for
the Bevacizumab group regarding BCVA improvement and
CMT decrease versus the laser group.
3. Combination Therapy
3.1. Intravitreal Triamcinolone plus Macular Laser Photo-
coagulation. A randomized controlled trial evaluated the
clinical outcome of macular laser photocoagulation after
intravitrealtriamcinolone acetonide(IVTA)fordiﬀuseDME
[29]. 86 eyes were included and randomized to two groups:
the laser group patients underwent IVTA and macular
grid photocoagulation 3 weeks afterward; the control group
patients were treated with IVTA only. The interval of 3 weeks
was chosen because of maximal therapeutic eﬀects of IVTA
at that time point.
MeanCMTwas538μatbaseline,250μafter3weeks,295
and 301μ at 3 and 6 months after IVTA in the laser group
versus 510, 227, 302, and 437μ in the control group. Visual
acuities were signiﬁcantly better in the laser group after 3
and 6 months. Though followup was short, it seems that
combination therapy maintains reduced CMT three months
after IVTA injection. As expected, almost 40% of patients in
both groups suﬀered IOP rise above 21mmHg; one patient
was referred to trabeculectomy.
3.2. Intravitreal Ranibizumab plus Macular Laser Photoco-
agulation (READ2). The multicenter, prospective, random-
ized Ranibizumab for Edema of the mAcula in Diabetes-2
(READ2) study (phase II) compared the eﬃcacy of intrav-
itreal ranibizumab with focal/grid laser and a combination
of both in 126 patients with DME [30]. Patients in the
ranibizumab group received 0.5mg ranibizumab at baseline
and at months 1, 3, and 5. The laser group was treated
with focal/grid laser photocoagulation at baseline and at
month 3 if needed. The combination treatment consisted
of focal/grid laser and ranibizumab injections at baseline
and at month 3. After the primary endpoint at 6 months,
all patients could receive ranibizumab injections according
to retreatment criteria: patients in the ranibizumab groupJournal of Ophthalmology 3
could have ranibizumab injections, patients in the laser
group could have laser or ranibizumab, and patients in the
combination group could have laser plus ranibizumab or
ranibizumab alone.
At month 6, the ranibizumab group gained signiﬁcantly
more BCVA than the laser and the combination group: 22%
improved ≥3 lines compared to 0% and 8%, respectively. At
two years, the visual outcome was not signiﬁcantly diﬀerent
in the three groups; the percentages of patients who gained
≥3 lines rose to 24, 18, and 26. The mean improvement
of BCVA was 7.4, 0.5, and 3.8 letters, respectively, at 6
months and 7.7, 5.1, and 6.8 letters at two years. 45%, 44%,
and 35% reached a Snellen equivalent of 20/40 or better.
Though there was a substantial decrease of mean foveal
thickness in the ranibizumab group at 6-month, it increased
duringthefurtherfollowup.Incontrast,therewasaconstant
decline in the two other groups during 24 months. This
implicates that additional macular laser photocoagulation
is auxiliary to decrease persistent or recurrent DME and
to reduce the number of required injections. Furthermore
the results show that patients with recurrent or persistent
DME after 6 months ranibizumab treatment maintain their
visual acuity gain by means of treatment continuation every
two months during a period of 18 months. Patients treated
previously by macular laser photocoagulation experienced a
signiﬁcant improvement of visual acuity after 18 months of
ranibizumab treatment.
3.3. Ranibizumab plus Prompt or Deferred Macular Laser
Photocoagulation versus Triamcinolone plus Macular Laser
Photocoagulation (DRCR.Net). The DRCR.net conducted a
multicenter, randomized clinical trial which included 854
eyes of 691 patients [31]. Eyes were randomized into four
treatment groups: prompt laser with sham injection, 0.5mg
of ranibizumab with prompt laser, 0.5mg of ranibizumab
with laser deferred for at least 24 weeks, and 4mg of
triamcinolone with prompt laser. At one year, the two
groups treated with ranibizumab had a signiﬁcant change in
mean VA from baseline. The triamcinolone and laser alone
groups did not show a signiﬁcant change in VA. Likewise,
signiﬁcantly more patients gained ≥10 letters in the two
ranibizumab groups than in the laser alone group (50%
and 47% versus 28%), and less patients lost ≥10 letters
(4% and 3% versus 13%). Notably, a subgroup analysis
of pseudophakic eyes in the triamcinolone group showed
similar results as for those in the ranibizumab groups. OCT
results paralleled visual acuity.
3.4. Ranibizumab plus Macular Laser Photocoagulation
(RESTORE). Similarly, the RESTORE study was a ran-
domized, double-masked, multicenter phase III study over
12 months that compared ranibizumab + sham laser and
ranibizumab + laser with laser + sham injection for DME
in 345 patients [32]. Ranibizumab or sham injections were
givenmonthlyforthreemonthsandthenPRN;laserorsham
laser was given at baseline and then PRN after an interval of
at least three months. In the ranibizumab and ranibizumab
+ laser groups a rapid improvement of VA was observed
50◦
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Figure 1: Fundus photograph of the left eye from a patient with




Figure 2: Late phase of ﬂuorescence angiography shows macular
leakagewithapetalloidpattern.Notemultiplemicroaneurysmsand
diﬀuse hyperﬂuorescence superotemporal to optic disc.
after one month which continued up to three months and
was sustained until month 12 (6.8 ± 8.3a n d6 .4 ± 11.8
letter gain, resp.), (Figure 3). The laser group maintained
stable VA and gained 0.9 letters at month 12. Likewise, the
percentage of patients reaching VA ≥ 20/40 was greater in
the two ranibizumab groups (53% in the ranibizumab group
and 44.9% in the ranibizumab + laser group versus 23.6% in
the laser group). Accordingly, CMT decreased signiﬁcantly
in the two laser groups. This study evaluated also health-
related quality of life by means of a questionnaire and found
a greater improvement in the two ranibizumab groups.
The number of PRN injections was about four in all three
groups; the need for PRN laser was also similar in all groups.
Summing up, ranibizumab monotherapy and combination
with laser treatment are superior to laser treatment alone for
DME. No diﬀerences in eﬃcacy were found between the two
ranibizumab groups.
3.5. PRP plus Macular Laser Photocoagulation plus Rani-
bizumab or Triamcinolone. The DRCR.net recently pub-
lished short-term results (14 weeks) of a phase 3, random-
ized, multicenter, clinical trial which addressed DME in
conjunction with panretinal photocoagulation (PRP) [33].
The study included 340 eyes with CSME and severe NPDR
orPDR(Figure 1).Patientswererandomizedtoreceivesham
injections or 0.5mg ranibizumab at baseline and at 4 weeks4 Journal of Ophthalmology
(a)
(b)
Figure 3: High-resolution OCT of the right eye of a patient with CSME. (a) shows loss of foveal contour and cystoid edema. (b) One month
after intravitreal avastin injection foveal contour is restored, retinal thickening decreased signiﬁcantly, and there are no cystoids spaces
detected anymore.
or 4mg IVTA at baseline and sham injection at 4 weeks.
Macular laser was performed within 3 to 10 days, and PRP
was initiated immediately or within 14 days of the baseline
injection. Mean change in visual acuity letter score from
baseline was signiﬁcantly better in the ranibizumab and
IVTAgroups.Thesetwogroupsalsohadagreaterproportion
ofeyeswhichimproved ≥10lettersandalowerproportionof
eyes which worsened ≥10 letters at 14 weeks. CMT changes
behaved similarly. After 14 weeks of followup patients were
evaluated after 56 weeks for safety information. At this point,
diﬀerences were not maintained.
3.6. Intravitreal Bevacizumab plus Triamcinolone. A clinical
trial by Soheilian et al. randomized 150 eyes with na¨ ıve
CSME into three groups: Bevacizumab + sham laser, beva-
cizumab + IVTA + sham laser, and macular laser photocoag-
ulation+shaminjection[34].Retreatmentwasperformedat




and the combination group. The laser group did not have
a signiﬁcant VA change. A statistically signiﬁcant greater
percentage of patients gained ≥2 lines in the bevacizumab
groups whereas a greater percentage of patients lost ≥2
lines in the laser group. All groups experienced a signiﬁcant
decrease of CMT at 6 weeks-without a signiﬁcant diﬀerence
between the groups.
Based upon the ﬁnding that visual outcome at 24
months was better for patients treated with bevacizumab
(alone or in combination with IVTA) than with laser, the
authors recommend considering bevacizumab as a ﬁrst-line
treatment. The addition of IVTA did not have an adjunctive
eﬀect. However, it should be noted that the study did not
assess combination of macular laser with bevacizumab or
IVTA as done by the DRCR.net. Another limiting factor is
the relative short followup.
3.7. Bevacizumab plus Macular Laser Photocoagulation. A
smaller clinical trial including 62 eyes with diﬀuse DME
evaluated the eﬃcacy of combined bevacizumab plus mac-
ular laser photocoagulation versus each alone as primary
treatment [35]. At month 1, patients in the bevacizumab
group and in the combined group experienced signiﬁcant
reduction in CMT—in contrast to patients treated by laser
only. Accordingly, the two groups treated with bevacizumab
had signiﬁcant improvement of VA whereas the laser group
did not have signiﬁcant change. After three and six months,
decreaseofCMTwassigniﬁcantonlyinthecombinedgroup.
A trend towards advantage for combined treatment was
also noticed with VA improvement and decrease of macular
leakageonFA(Figure 2).Atsixmonths,VAevenregressedtoJournal of Ophthalmology 5
baseline values in the laser and bevacizumab groups whereas
the improvement in the combined group was not statistically
signiﬁcant. It should be noted that there was no masking by
sham treatment in this study.
4. Discussion
Since the results of the ETDRS, macular laser photocoag-
ulation has been considered the mainstay of treatment for
DME although visual outcomes have not been satisfactory
[4].The introductionofintravitrealcorticosteroids andanti-
VEGFtreatmentschangedtheperspectiveonmacularedema
in general and on DME in particular.
Though the studies mentioned above had diﬀerent de-
signs, some ﬁndings are consistent.
Ranibizumab monotherapy and ranibizumab in com-
bination with laser are more eﬀective than macular laser
photocoagulation monotherapy. For bevacizumab, superi-
ority has been shown for combination with macular laser
photocoagulation to each of them alone.
Theadditivesynergisticeﬀectoflasertoanti-VEGFtreat-
ment can be explained by several mechanisms. Decreased
foveal thickness facilitates laser treatment and reduces the
need for high laser energy. Furthermore, more marked and
prolonged reduction in macular thickness is achieved. Beva-
cizumab and ranibizumab downregulate VEGF and reduce
capillary permeability. However, VEGF is only one factor in
a complex pathogenetic process, and macular hypoxia as an
underlying problem is not addressed. This may explain
the rapid recurrence of macular edema a few weeks after
injection when VEGF levels again increase in the vitreous.
Grid laser photocoagulation decreases oxygen consumption
by destroying photoreceptors. Hence, combining anti-VEGF
with laser photocoagulation is a complementary treatment
with high eﬃcacy in treating DME and decreasing recur-
rence.
Combination therapy of IVTA plus macular laser is more
eﬀective than either monotherapy and may be comparable
to anti-VEGF plus laser in pseudophakic patients. The
success of this combination therapy may be due to several
mechanisms: IVTA decreases foveal thickness and allows
more precise and eﬀective macular laser photocoagulation
withlowerenergylevelsneeded.Furthermore,steroidsmight
promote the formation of mature laser scars. A deterioration
of macular edema is a well-known complication of laser
treatment. Intravitreal therapeutic levels of steroids seem to
be protective and even modulate the RPE modeling after
laser.
PRP frequently causes exacerbation of DME. Prompt
laser with IVTA or ranibizumab treatment results in better
visual acuity and reduced CMT in the short term.
Thoughintravitrealcorticosteroidsandanti-VEGFdrugs
have diﬀerent ways of action there was no adjunctive eﬀect
found with combination therapy.
Since macular laser photocoagulation was ﬁrst estab-
lished by the ETDRS, treatment strategy for DME has
essentially changed. Diﬀerent treatment approaches reﬂect
the complex pathogenesis of the disease. However, refractory
cases still exist even with combination therapies. Due to
heterogeneityamongpatientstherewillbenoidealtreatment
regimen for everybody. Further investigation of additional
treatment options is needed in order to optimize therapy.
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